Scientists dig into old records to unlock secrets of rare adrenal cancer
NCT ID NCT04358107
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks back at medical records from 1,000 people with adrenocortical carcinoma (ACC), a rare and serious cancer. Researchers want to see how factors like age, sex, race, and tumor burden relate to survival and treatment response. No new treatments are given; instead, the team analyzes data from previous studies to find patterns that could guide future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better predict outcomes and choose treatments for people with adrenocortical cancer.
- What could go wrong
- This is a retrospective review of old data, not a new treatment trial. It may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute (NCI)
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver tumors targeted directly: old pump, new drug
- Study aims to uncover hidden side effects of common adrenal cancer drug
- New registry aims to unlock secrets of rare adrenal cancer
- Scientists search for keys to unlock immune attack on rare adrenal cancer
- Scientists investigate adrenal tumors and seek better therapies
- New hope for rare cancers? drug combo shows promise in early trial